Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials

Addiction

Volumn 113, Issue 5, 2018, Pages 805-816

  Rosen, Laura J ^a   Galili, Tal ^a   Kott, Jeffrey ^a   Goodman, Mark ^a   Freedman, Laurence S ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

Bupropion (Zyban); cessation medications; meta analysis; nicotine replacement therapy (NRT); sustained abstinence; varenicline (Chantix, Champix)

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

DRUG THERAPY; HUMAN; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SMOKING CESSATION; TIME FACTOR; TREATMENT OUTCOME;

BUPROPION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; SMOKING CESSATION AGENTS; TIME FACTORS; TOBACCO USE CESSATION DEVICES; TREATMENT OUTCOME; VARENICLINE;

EID: 85041128223     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.14134     Document Type: Review

References (46)

1. The Tobacco Atlas: Tobacco Deaths 2016. Available at: http://www.tobaccoatlas.org/topic/smokings-death-toll/ (accessed 22 December 2016) (Achived at http://www.webcitation.org/6wOMY1YIb on 11 January 2018).
2. World Health Organization (WHO). WHO Report on the Global Tobacco Epidemic, 2011: Warning About the Dangers of Tobacco. Geneva, Switzerland: WHO; 2011. (Available at: http://www.who.int/tobacco/global_report/2011/en/ (accessed 11 January 2018) (Archived at http://www.webcitation.org/6wOMtmIsP on 11 January 2018)
3. World Health Organization. Tobacco: Fact Sheet 2017. Available at: http://www.who.int/mediacentre/factsheets/fs339/en/ (accessed 20 September 2017) (Archived at http://www.webcitation.org/6wONFjN7v on 11 January 2018).
4. Jha P., Chaloupka F. The economics of global tobacco control. BMJ 2000; 321: 358–361.
5. Fiore M., Jaen C. R., Baker T., Bailey W., Benowitz N., Curry S. J. et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services; 2008.
6. Cahill K., Stead L. F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; Issue 4. Art. No.: CD006103. https://doi.org/10.1002/14651858.CD006103.pub6.
7. Hughes J. R., Stead L. F., Hartmann-Boyce J., Cahill K., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014; Issue 1. Art. No.: CD000031. https://doi.org/10.1002/14651858.CD000031.pub4.
8. Stead L. F., Perera R., Bullen C., Mant D., Hartmann-Boyce J., Cahill K. et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; Art. No.: CD000146. https://doi.org/10.1002/14651858.CD000146.pub4.
9. National Institute for Clinical Excellence (NICE). Varenicline for smoking cessation 2007. Available at: http://www.who.int/mediacentre/factsheets/fs339/en/ (accessed 11 January 2018) (Archived at http://www.webcitation.org/6wONFjN7v on 11 January 2018).
10. Eisenberg M. J., Filion K. B., Yavin D., Bélisle P., Mottillo S., Joseph L. et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Can Med Assoc J 2008; 179: 135–144.
11. Etter J.-F., Stapleton J. A. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006; 15: 280–285.
12. Windle S. B., Filion K. B., Mancini J. G., Adye-White L., Joseph L., Gore G. C. et al. Combination therapies for smoking cessation: a hierarchical Bayesian meta-analysis. Am J Prev Med 2016; 51: 1060–1071.
13. Wu P., Wilson K., Dimoulas P., Mills E. J. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006; 6: 300.
14. Hajek P., Stead L. F., West R., Jarvis M., Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009; Issue 1. Art. No.: CD003999. https://doi.org/10.1002/14651858.CD003999.pub3.
15. Stapleton J. A., Sutherland G., Russell M. A. How much does relapse after one year erode effectiveness of smoking cessation treatments? Long term follow up of randomised trial of nicotine nasal spray. BMJ 1998; 316: 830–831.
16. Hughes J. R., Keely J., Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99: 29–38.
17. Zhou X., Nonnemaker J., Sherrill B., Gilsenan A. W., Coste F., West R. Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. Addict Behav 2009; 34: 365–373.
18. Glavas D., Rumboldt M., Rumboldt Z. Smoking cessation with nicotine replacement therapy among health care workers: randomized double-blind study. Croat Med J 2003; 44: 219–224.
19. Richmond R. L., Makinson R. J., Kehoe L. A., Giugni A. A., Webster I. W. One-year evaluation of three smoking cessation interventions administered by general practitioners. Addict Behav 1993; 18: 187–199.
20. Tonnesen P., Lauri H., Perfekt R., Mann K., Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J 2012; 40: 548–554.
21. Pierce J., Gilpin E. A. Pharmaceutical aids for smoking cessation impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002; 288: 1260–1264.
22. Baker T. B., Piper M. E., Stein J. H., Smith S. S., Bolt D. M., Fraser D. L. et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial. JAMA 2016; 315: 371–379.
23. West R. The clinical significance of ‘small’ effects of smoking cessation treatments. Addiction 2007; 102: 506–509.
24. Hughes JR, Keely JP, Niaura R. S., Ossip-Klein D. J., Richmond R. L., Swan G. E. et al. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003;5:13–25.
25. Hughes J. R., Callas P. W. Errors in interpreting abstinence curves in studies of smoking cessation. Nicotine Tob Res 2006; 8: 7–12.
26. Piepoli M. F., Hoes A. W., Agewall S., Albus C., Brotons C., Catapano A. L. et al. European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 37: 2315–2381.
27. Cahill K, Stevens S, Perera R., Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; Issue 5. Art. No.: CD009329. https://doi.org/10.1002/14651858.CD009329.pub2.
28. Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0 ed 2011:16.2.2 Intent-to-treat issues for dichotomous data. Available at: http://training.cochrane.org/handbook (accessed 4 January 2018) (Archived at http://www.webcitation.org/6wOO5Uzyu on 11 January 2018).
29. West R., Hajek P., Stead L., Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299–303.
30. Shenhav L., Heller R., Benjamini Y. Quantifying replicability in systematic reviews: the r-value. arXiv preprint arXiv:1502.00088; 2015. Available at: https://arxiv.org/pdf/1502.00088.pdf (accessed 17 January 2018).
31. R Core Team R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.
32. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1–48.
33. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2009.
34. Stapleton J. Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res 1998; 7: 187–203.
35. Amodei N., Lamb R. J. Over-the-counter nicotine replacement therapy: can its impact on smoking cessation be enhanced? Psychol Addict Behav 2008; 22: 472–485.
36. Cummings K. M., Hyland A. Impact of nicotine replacement therapy on smoking behavior. Annu Rev Public Health 2005; 26: 583–599.
37. Walsh R. A. Australia's experience with varenicline: usage, costs and adverse reactions. Addiction 2011; 106: 451–452.
38. Pierce J. P., Cummins S. E., White M. M., Humphrey A., Messer K. Quitlines and nicotine replacement for smoking cessation: do we need to change policy? Annu Rev Public Health 2012; 33: 341–356.
39. Gilpin E. A., Messer K., Pierce J. P. Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success? Nicotine Tob Res 2006; 8: 661–669.
40. Walsh R. A., Penman A. G. The effectiveness of nicotine replacement therapy over-the-counter. Drug Alcohol Rev 2000; 19: 243–247.
41. Chapman S., MacKenzie R. The global research neglect of unassisted smoking cesssation: causes and consequences. PLOS Med 2010; 7: e1000216.
42. Walsh R. A. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev 2008; 27: 529–547.
43. Hall S. M., Humfleet G. L., Reus V. I., Munoz R. F., Hartz D. T., Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59: 930–936.
44. Levine M. D., Perkins K. A., Kalarchian M. A., Cheng Y., Houck P. R., Slane J. D. et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med 2010; 170: 543–550.
45. McCarthy D. E., Piasecki T. M., Lawrence D. L., Jorenby D. E., Shiffman S., Fiore M. C. et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res 2008; 10: 717–729.
46. Piper M. E., Federman E. B., McCarthy D. E., Bolt D. M., Smith S. S., Fiore M. C. et al. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res 2007; 9: 947–954.